Major improvement in thyroid cancer survival of elderly patients in the Nordic countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F24%3A10478585" target="_blank" >RIV/00216208:11140/24:10478585 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6.GKRCQq8N" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6.GKRCQq8N</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ejendo/lvae015" target="_blank" >10.1093/ejendo/lvae015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Major improvement in thyroid cancer survival of elderly patients in the Nordic countries

Popis výsledku v původním jazyce

Objectives We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.Design Population-based survival study.Methods Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.Results In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.Conclusions Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.

Název v anglickém jazyce

Major improvement in thyroid cancer survival of elderly patients in the Nordic countries

Popis výsledku anglicky

Objectives We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.Design Population-based survival study.Methods Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.Results In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.Conclusions Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Endocrinology

ISSN

0804-4643

e-ISSN

1479-683X

Svazek periodika

190

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

"K32"-"K36"

Kód UT WoS článku

001180121100001

EID výsledku v databázi Scopus

2-s2.0-85187342890